Ποια είναι η τιμή για RaQualia Pharma Inc. (4579)

Η τιμή για RaQualia Pharma Inc. (4579) είναι $3.69

Ποια είναι η κεφαλαιοποίηση αγοράς για RaQualia Pharma Inc. (4579)

Η κεφαλαιοποίηση αγοράς για RaQualia Pharma Inc. (4579) είναι $90.16M

RaQualia Pharma Inc. (4579) Τιμή και Κεφαλαιοποίηση Αγοράς

RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.

Η τιμή για 4579	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$213,071 $90.16M	NVDA	$5.211T	+5,780,014.15%
$185,897 $90.16M	AAPL	$4.547T	+5,042,857.31%
$170,186 $90.16M	GOOG	$4.162T	+4,616,649.79%
$146,894 $90.16M	MSFT	$3.593T	+3,984,791.67%
$114,188 $90.16M	AMZN	$2.793T	+3,097,553.82%

Η τιμή για 4579

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$213,071 $90.16M